real-time news and commentary for investors
Thursday, Jul 5
2012, 4:08 PM
GlaxoSmithKline's (GSK) $3B hit from the DoJ earlier this week is being billed as the...
GlaxoSmithKline's (GSK) $3B hit from the DoJ earlier this week is being billed as the “largest health care fraud settlement in U.S. history... unprecedented in both size and scope.” And nobody cares. Why? Because investors know that over the past decade, the two drugs behind the scandal, Paxil an Wellbutrin, together brought in more than seven times the amount of the settlement. Paxil brought in close to $14B, and Wellbutrin $8.5B. As is frequently the case in cases of corporate misdoings, crime and punishment aren't always relative.